Elizabeth Vickers Saarel

Elizabeth Vickers Saarel

Auto-generated profile, based on publicly available information

Elizabeth Vickers Saarel

Department of Pediatric Cardiology, Cleveland Clinic Children’s Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
MCMina K. Chung
Mina K. Chung
AFAngela Fagerlin
Angela Fagerlin
PWPaul J. Wang
Paul J. Wang
TATinuola B. Ajayi
Tinuola B. Ajayi
LALarry A. Allen
Larry A. Allen
JWJennifer M. Wright
Jennifer M. Wright
Shared decision making (SDM) has been advocated to improve patient care, patient decision acceptance, patient-provider communication, patient motivation, adherence, and patient reported outcomes. Documentation of SDM is endorsed in several society guidelines and is a condition of reimbursement for selected cardiovascular and cardiac arrhythmia procedures. However, many clinicians argue that SDM already occurs with clinical encounter discussions or the process of obtaining informed consent and note the additional imposed workload of using and documenting decision aids without validated tools or evidence that they improve clinical outcomes. In reality, SDM is a process and can be done without decision tools, although the process may be variable. Also, SDM advocates counter that the low-risk process of SDM need not be held to the high bar of demonstrating clinical benefit and that increasing the quality of decision making should be sufficient. Our review leverages a multidisciplinary group of experts in cardiology, cardiac electrophysiology, epidemiology, and SDM, as well as a patient advocate. Our goal is to examine and assess SDM methodology, tools, and available evidence on outcomes in patients with heart rhythm disorders to help determine the value of SDM, assess its possible impact on electrophysiological procedures and cardiac arrhythmia management, better inform regulatory requirements, and identify gaps in knowledge and future needs.

1 April 2019 in Heart Rhythm
Verified
Journal Article
Closed access
BOBrian Olshansky
Brian Olshansky
GAGourg Atteya
Gourg Atteya
DCDavid Cannom
David Cannom
HHHein Heidbuchel
Hein Heidbuchel
ESElizabeth V. Saarel
Elizabeth V. Saarel
RLRachel Lampert
Rachel Lampert

13 August 2024 in Circulation
Verified
Journal Article
Closed access
RLRachel Lampert
Rachel Lampert
SDSharlene Day
Sharlene Day
BABarbara Ainsworth
Barbara Ainsworth
MBMatthew M Burg
Matthew M Burg
BMBradley S. Marino
Bradley S. Marino
MAMichael J. Ackerman
Michael J. Ackerman
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.

1 October 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MJMichael X. Jiang
Michael X. Jiang
EBEugene H. Blackstone
Eugene H. Blackstone
TKTara Karamlou
Tara Karamlou
JGJoanna Ghobrial
Joanna Ghobrial
EBEllen K. Brinza
Ellen K. Brinza
ESElizabeth V. Saarel
Elizabeth V. Saarel

1 July 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
SAShahnawaz Amdani
Shahnawaz Amdani
GBGerard Boyle
Gerard Boyle
ESElizabeth V. Saarel
Elizabeth V. Saarel
JGJustin Godown
Justin Godown
Wei LiuWei Liu
Wei Liu
TKTara Karamlou
Tara Karamlou
Although outcomes for pediatric cardiomyopathy (CMP) patients have improved, an understanding of outcomes by CMP phenotype is essential. This study assessed changes in waitlist and post-transplant survival in nondilated cardiomyopathy (DCM) patients over 2 decades, explored ventricular assist device (VAD) utilization in this cohort, and identified risk factors for waitlist and posttransplant mortality in the current era. Pediatric patients with a diagnosis of CMP listed for heart transplantation during three eras: Era 1: March 5, 1999 to December 31, 2004; Era 2: January 1, 2005 to December 15, 2011; and Era 3 (current era): December 16, 2011 to February 28, 2018 were included. Multivariable Cox proportional hazards regression was performed to assess waitlist and posttransplant survival. Compared with patients with DCM, those with hypertrophic and restrictive cardiomyopathy in the current era are less likely to be on VAD (23.4% vs 2.7% vs 4.5%); listed United Network for Organ Sharing Status 1A (75.6% vs 39.8% vs 34.8%), and more likely to have longer waitlist times (P < .01 for all). Only 3.3% hypertrophic and 2.4% restrictive cardiomyopathy patients had VAD implantation, although VAD use did not adversely impact waitlist survival in weighted non-DCM patients. Significant improvements have occurred in waitlist survival of hypertrophic and posttransplant survival of both types of non-DCM patients. Currently, waitlist and posttransplant survival is similar for all CMP phenotypes. VAD use is low in patients with non-DCM, although this did not increase waitlist mortality in adjusted analysis. Further studies in patients with non-DCM are needed to determine optimal timing and anatomic characteristics most likely to benefit from VAD implantation during the waitlist period.

1 March 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SBSalima A. Bhimani
Salima A. Bhimani
EHEileen Hsich
Eileen Hsich
GBGerard Boyle
Gerard Boyle
WLWei Liu
Wei Liu
SWSarah Worley
Sarah Worley
SAShahnawaz Amdani
Shahnawaz Amdani